JP2013506622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506622A5 JP2013506622A5 JP2012525756A JP2012525756A JP2013506622A5 JP 2013506622 A5 JP2013506622 A5 JP 2013506622A5 JP 2012525756 A JP2012525756 A JP 2012525756A JP 2012525756 A JP2012525756 A JP 2012525756A JP 2013506622 A5 JP2013506622 A5 JP 2013506622A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding portion
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23579909P | 2009-08-21 | 2009-08-21 | |
| US61/235,799 | 2009-08-21 | ||
| PCT/US2010/046364 WO2011022727A2 (en) | 2009-08-21 | 2010-08-23 | Antibodies against the ectodomain of erbb3 and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013506622A JP2013506622A (ja) | 2013-02-28 |
| JP2013506622A5 true JP2013506622A5 (enExample) | 2013-10-10 |
| JP5752687B2 JP5752687B2 (ja) | 2015-07-22 |
Family
ID=43607614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012525756A Ceased JP5752687B2 (ja) | 2009-08-21 | 2010-08-23 | Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP2467164A2 (enExample) |
| JP (1) | JP5752687B2 (enExample) |
| KR (1) | KR20120059568A (enExample) |
| CN (1) | CN103002912A (enExample) |
| AU (1) | AU2010284018C1 (enExample) |
| BR (1) | BR112012003809A2 (enExample) |
| CA (1) | CA2771744A1 (enExample) |
| CR (1) | CR20120108A (enExample) |
| DO (1) | DOP2012000044A (enExample) |
| EA (1) | EA201200195A1 (enExample) |
| EC (1) | ECSP12011740A (enExample) |
| IL (1) | IL218097A0 (enExample) |
| IN (1) | IN2012DN01518A (enExample) |
| MA (1) | MA33582B1 (enExample) |
| MX (1) | MX336091B (enExample) |
| NI (1) | NI201200027A (enExample) |
| PE (1) | PE20121585A1 (enExample) |
| SG (1) | SG178509A1 (enExample) |
| TN (1) | TN2012000057A1 (enExample) |
| WO (1) | WO2011022727A2 (enExample) |
| ZA (1) | ZA201201195B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2129396T3 (pl) | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| KR101806323B1 (ko) * | 2009-11-13 | 2017-12-07 | 다이이치 산쿄 유럽 게엠베하 | Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법 |
| CA2782571C (en) | 2009-12-22 | 2018-01-23 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| BR112012025730B1 (pt) | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão |
| PL2606070T3 (pl) | 2010-08-20 | 2017-06-30 | Novartis Ag | Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| IT1402149B1 (it) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2. |
| EP3156421B1 (en) | 2010-11-01 | 2018-06-06 | Symphogen A/S | Pan-her antibody composition |
| KR20140138353A (ko) | 2011-04-19 | 2014-12-03 | 메리맥 파마슈티컬즈, 인크. | 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체 |
| AU2012274461A1 (en) * | 2011-06-20 | 2014-01-16 | Kyowa Hakko Kirin Co., Ltd. | Anti-erbB3 antibody |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| CA2849508C (en) | 2011-09-30 | 2020-12-22 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| AU2012318541B2 (en) | 2011-10-06 | 2018-04-12 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
| CA2855298A1 (en) * | 2011-11-09 | 2013-05-16 | The Uab Research Foundation | Her3 antibodies and uses thereof |
| AU2012349735B2 (en) | 2011-12-05 | 2016-05-19 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| WO2013124297A1 (en) * | 2012-02-22 | 2013-08-29 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| US20160232293A1 (en) * | 2013-10-17 | 2016-08-11 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| ES2816624T3 (es) * | 2014-02-28 | 2021-04-05 | Merus Nv | Anticuerpos que se unen a EGFR y ERBB3 |
| CN105367657B (zh) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
| JP2017534574A (ja) | 2014-09-08 | 2017-11-24 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| KR20250157457A (ko) | 2015-10-23 | 2025-11-04 | 메뤼스 엔.페. | 암 성장을 억제하는 결합 분자 |
| WO2018182422A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
| CN111148764B (zh) | 2017-05-17 | 2025-08-12 | 美勒斯公司 | 用于乳腺癌的ErbB-2/ErbB-3双特异性抗体与内分泌治疗的组合 |
| PL3665198T3 (pl) | 2017-08-09 | 2025-06-09 | Merus N.V. | Przeciwciała wiążące egfr i cmet |
| WO2019028555A1 (en) | 2017-08-09 | 2019-02-14 | University Of Saskatchewan | HER3 BINDING AGENTS AND USES THEREOF |
| GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
| JP2021534811A (ja) * | 2018-06-22 | 2021-12-16 | シーアールディー ファーマシューティカルズ インコーポレイティド | 抗ｈｅｒ３抗体およびその用途 |
| AU2021360625A1 (en) * | 2020-10-14 | 2023-06-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof |
| AU2021382717A1 (en) * | 2020-11-20 | 2023-07-06 | Actinium Pharmaceuticals, Inc. | Her3 radioimmunotherapy for the treatment of solid cancers |
| CA3222478A1 (en) * | 2021-06-15 | 2022-12-22 | Xiaoyan Zhong | Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof |
| WO2023198138A1 (zh) * | 2022-04-13 | 2023-10-19 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段及其医药用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2129396T3 (pl) * | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
-
2010
- 2010-08-23 SG SG2012011664A patent/SG178509A1/en unknown
- 2010-08-23 CN CN2010800477186A patent/CN103002912A/zh active Pending
- 2010-08-23 MX MX2012002172A patent/MX336091B/es unknown
- 2010-08-23 EA EA201200195A patent/EA201200195A1/ru unknown
- 2010-08-23 PE PE2012000234A patent/PE20121585A1/es not_active Application Discontinuation
- 2010-08-23 BR BR112012003809A patent/BR112012003809A2/pt not_active IP Right Cessation
- 2010-08-23 EP EP10810721A patent/EP2467164A2/en not_active Withdrawn
- 2010-08-23 IN IN1518DEN2012 patent/IN2012DN01518A/en unknown
- 2010-08-23 WO PCT/US2010/046364 patent/WO2011022727A2/en not_active Ceased
- 2010-08-23 CA CA2771744A patent/CA2771744A1/en not_active Abandoned
- 2010-08-23 KR KR1020127007280A patent/KR20120059568A/ko not_active Withdrawn
- 2010-08-23 AU AU2010284018A patent/AU2010284018C1/en not_active Ceased
- 2010-08-23 JP JP2012525756A patent/JP5752687B2/ja not_active Ceased
-
2012
- 2012-02-09 TN TNP2012000057A patent/TN2012000057A1/en unknown
- 2012-02-14 IL IL218097A patent/IL218097A0/en unknown
- 2012-02-15 NI NI201200027A patent/NI201200027A/es unknown
- 2012-02-17 ZA ZA2012/01195A patent/ZA201201195B/en unknown
- 2012-02-20 DO DO2012000044A patent/DOP2012000044A/es unknown
- 2012-03-05 CR CR20120108A patent/CR20120108A/es unknown
- 2012-03-12 MA MA34684A patent/MA33582B1/fr unknown
- 2012-03-21 EC ECSP12011740 patent/ECSP12011740A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013506622A5 (enExample) | ||
| CN102421802B (zh) | 人源化的axl抗体 | |
| CN108752476B (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| US10058610B2 (en) | Methods for treating cancer by administering humanized pan-HER antibody compositions | |
| EP3470435B1 (en) | Antibody that binds erbb-2 and erbb-3 | |
| JP7065935B2 (ja) | 抗ｌｙ６ｇ６ｄ抗体及び使用方法 | |
| JP2020520370A (ja) | 抗ＳＩＲＰα抗体 | |
| CN106232139A (zh) | 双特异性her2抗体 | |
| JP2017149720A5 (enExample) | ||
| JP2010518820A5 (enExample) | ||
| BR112015011518B1 (pt) | Anticorpo heterodimérico, ácido nucleico e vetor | |
| JP2014522850A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| US20240294622A1 (en) | Novel anti-gremlin1 antibodies | |
| US20250136720A1 (en) | Bispecific and tetravalent cd137 and fap molecules for the treatment of cancer | |
| JP2020513759A5 (enExample) | ||
| AU2019233694A1 (en) | De-immunised anti-ERBB3 antibodies | |
| US20230357391A1 (en) | Cd47 binding agents and uses thereof | |
| WO2023078386A1 (zh) | 抗cldn18.2抗体及其用途 | |
| WO2023227115A1 (en) | A method of treating solid tumor | |
| TW202540198A (zh) | 雙特異性抗體樣蛋白以及彼之製造及使用方法 | |
| TW202540199A (zh) | 靶向her2及her3之雙特異性四價抗體 | |
| JPWO2021173832A5 (enExample) | ||
| HK40051621A (en) | Antibody that binds erbb-2 and erbb-3 | |
| HK40006122A (en) | Antibody that binds erbb-2 and erbb-3 |